59338-84-0

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 4-amino-5-nitro-o-anisate is utilized as a key intermediate in the synthesis of pharmaceutical drugs. Its unique structure, which includes a nitro group and an amino group attached to an o-anisate group, allows for the development of a wide range of pharmaceutical products with diverse therapeutic applications.
Used in Organic Chemistry:
methyl 4-amino-5-nitro-o-anisate is also employed in the synthesis of dyes and pigments, showcasing its versatility and value in the field of organic chemistry. Its ability to be incorporated into various organic compounds makes it an essential component in the development of new materials and products.

InChI:InChI=1/C8H8N2O5/c1-15-7-3-5(9)6(10(13)14)2-4(7)8(11)12/h2-3H,9H2,1H3,(H,11,12)

Upstream product

• 4093-41-8 methyl 4-acetamido-2-methoxy-5-nitrobenzoate 
• 27492-84-8 Methyl 4-amino-2-methoxybenzoate 
• 4093-29-2 methyl 4-(acetylamino)-o-anisate 

Downstream Products

• 755035-23-5 methyl 4-{[5-chloro-2-(methoxycarbonyl)phenyl]amino}-2-methoxy-5-nitrobenzoate 
• 42832-23-5 methyl 4-(dimethylamino)-2-methoxy-5-nitrobenzoate 
• 59338-86-2 6-methoxy-1H-benzotriazole-5-carboxylic acid methyl ester 
• 59338-85-1 methyl-4,5-diamino-2-methoxybenzoate 

Relevant academic research and scientific papers

ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-I' PATHWAY AND METHODS OF USE THEREOF

The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.

ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-I" PATHWAY AND METHODS OF USE THEREOF

The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.

As neuroprotective agents of pharmaceutical compounds

The invention discloses a medicinal compound as a neuroprotective agent. The medicinal compound is a neuronal nitric oxide synthase-postsynaptic density protein 95 (nNOS-PSD95) decoupling agent. The medicinal compound is a benzene ring derivative shown in the general formula (I) or its pharmaceutically acceptable salt. The invention further discloses a preparation method of the medicinal compound and a use of the medicinal compound in prevention and treatment on neuronal damage influence-caused diseases.

Similar but different: Thermodynamic and structural characterization of a pair of enantiomers binding to acetylcholinesterase

Take a closer look: Unexpectedly, a pair of enantiomeric ligands proved to have similar binding affinities for acetylcholinesterase. Further studies indicated that the enantiomers exhibit different thermodynamic profiles. Analyses of the noncovalent interactions in the protein-ligand complexes revealed that these differences are partly due to nonclassical hydrogen bonds between the ligands and aromatic side chains of the protein. Copyright

Investigation of novel 7,8-disubstituted-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-ones as potent Chk1 inhibitors

The synthesis and structure-activity relationships (SAR) of Chk1 inhibitors based on a 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one core are described. Specifically, an exploration of the 7 and 8 positions on this previously disclosed core afforded compounds with improved enzymatic and cellular potency.

HETEROCYCLIC KINASE INHIBITORS

Compounds having the formula (I) are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.